WallStSmart

IQVIA Holdings Inc (IQV)vsInotiv Inc (NOTV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IQVIA Holdings Inc generates 3073% more annual revenue ($16.31B vs $514.03M). IQV leads profitability with a 8.3% profit margin vs -13.5%. IQV earns a higher WallStSmart Score of 72/100 (B).

IQV

Strong Buy

72

out of 100

Grade: B

Growth: 6.0Profit: 7.0Value: 10.0Quality: 4.3
Piotroski: 4/9Altman Z: 1.33

NOTV

Avoid

34

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IQVUndervalued (+49.1%)

Margin of Safety

+49.1%

Fair Value

$348.46

Current Price

$165.64

$182.82 discount

UndervaluedFair: $348.46Overvalued

Intrinsic value data unavailable for NOTV.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IQV3 strengths · Avg: 8.3/10
Return on EquityProfitability
21.4%9/10

Every $100 of equity generates 21 in profit

PEG RatioValuation
0.978/10

Growing faster than its price suggests

EPS GrowthGrowth
23.6%8/10

Earnings expanding 23.6% YoY

NOTV1 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Areas to Watch

IQV1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
1.332/10

Distress zone — elevated risk

NOTV4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$11.24M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-49.8%2/10

ROE of -49.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bull Case : NOTV

The strongest argument for NOTV centers on Price/Book.

Bear Case : IQV

The primary concerns for IQV are Altman Z-Score.

Bear Case : NOTV

The primary concerns for NOTV are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

IQV profiles as a value stock while NOTV is a turnaround play — different risk/reward profiles.

NOTV carries more volatility with a beta of 4.22 — expect wider price swings.

IQV is growing revenue faster at 10.3% — sustainability is the question.

IQV generates stronger free cash flow (561M), providing more financial flexibility.

Bottom Line

IQV scores higher overall (72/100 vs 34/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Inotiv Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. The company is headquartered in West Lafayette, Indiana.

Want to dig deeper into these stocks?